Who Paid My Doc
Nathan Kobrinsky
Pediatric Hematology-Oncology Fargo, ND Medical Doctor
NPI 1659398329 CMS profile 166409
2101 Elm Street N, Fargo, ND 58102
General payments
$12,808
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Nathan Kobrinsky of Fargo, ND is reported in the CMS Open Payments database as having received $12,808 across 24 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $122 | 1 | |
| 2022 | General | $69 | 1 | |
| 2021 | General | $13 | 1 | |
| 2019 | General | $12,604 | 21 |
Beside peers
- Nathan Kobrinsky
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Nathan Kobrinsky were reported at $0. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Nathan Kobrinsky | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12,604 | $184 | $69–$2,094 | $163 |
| 2020 | $0 | $220 | $37–$3,941 | $114 |
| 2021 | $13 | $366 | $63–$4,909 | $132 |
| 2022 | $69 | $181 | $66–$2,775 | $149 |
| 2023 | $122 | $175 | $62–$2,600 | $160 |
| 2024 | $0 | $227 | $66–$2,992 | $164 |
| 2025 | $0 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 38 drugsPart D claims
982
Drug cost
$158,546
Branded share of claims
40.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 172 | $106,041 | |
| Xarelto Rivaroxaban | Brand | 51 | $36,024 | |
| Levothyroxine Sodium | Generic | 34 | $2,638 | |
| Amlodipine-Valsartan-Hctz Amlodipine/Valsartan/Hcthiazid | Brand | 13 | $1,721 | |
| Ondansetron Hcl Ondansetron Hcl/Pf | Brand | 21 | $1,099 | |
| Hydroxyurea | Generic | 22 | $888 | |
| Rosuvastatin Calcium | Generic | 71 | $873 | |
| Celecoxib | Generic | 26 | $867 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 25 | $789 | |
| Klor-Con M20 Potassium Chloride | Brand | 14 | $740 |
The 10 drugs with the highest cost, of 38 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$32,489
Medicare patients
121
Services billed
331
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Ischemic heart disease | 43% | |
| Chronic kidney disease | 39% | |
| Diabetes | 29% | |
| Heart failure | 26% | |
| Depression | 26% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pediatric Hematology-Oncology in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.